Company holds exclusive rights to family of
polyunsaturated fatty acid (PUFA) analogs
New patent covers proprietary analogs in
the treatment of neurodegenerative diseases
NEW
YORK, July 18, 2024 /PRNewswire/ --
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the
"Company"), an emerging biopharmaceutical company developing
therapeutics for neurodegenerative disorders, today announced a new
collaboration agreement with LSU Health New Orleans' Neuroscience
Center of Excellence for pre-clinical testing of the Company's
polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal
cord injury (SCI). The Company also announced that the US
Patent and Trademark Office (USPTO) recently issued US Patent No.
12,016,837 titled 'Halogenated Esters of Cyclopropanated
Unsaturated Fatty Acids for Use in the Treatment of
Neurodegenerative Diseases,' covering its family of
analogs. The studies will compare the analogs with Bryostatin
in SCI.
"We are excited to begin this new collaboration with
Synaptogenix to test the regenerative properties of Bryostatin and
related compounds on our preclinical model of Spinal Cord Injury,"
stated Dr. Nicolas Bazan, Director,
Neuroscience Center of Excellence, LSU Health New
Orleans.
"Dr. Nicolas Bazan is a
world-renowned neuroscientist with an extensive body of
innovative research on neuroprotection and brain damage
dating over three decades," said Dr. Alan
Tuchman, Chief Executive Officer of Synaptogenix. "We
look forward to a robust study of our PUFA drug prototypes at his
LSU Health New Orleans neuroscience lab. We believe these assets
represent a potential source for follow-on drug candidates," Dr.
Tuchman added.
Synaptogenix holds exclusive rights to its PUFA analogs pursuant
to a licensing agreement with Cognitive Research Enterprises, Inc.
(CRE), formerly known as the Blanchette Rockefeller Neurosciences
Institute.
"Earlier pre-clinical testing by CRE showed positive results
from the PUFA analogs in slowing or reversing several
neurodegenerative disease processes in Alzheimer's disease, and
positive outcomes in synaptogenesis, anti-amyloid and anti-tau
tangles, and prevention of neuronal death," said Dr. Daniel Alkon, President and CSO of Synaptogenix.
"We are developing and patenting this class of compounds as a
next-generation treatment for neurodegenerative diseases."
Like Bryostatin-1, the PUFA analogs are activators of the enzyme
PKC epsilon (PKC ε), but the analogs are structurally different
from Bryostatin-1 and activate PKC ε at a different site on the
enzyme. PKC ε activation has been shown in preclinical in
vivo models to play a key role in slowing or reversing several
neurodegenerative disease processes in stroke, Alzheimer's disease
(AD), ALS (Lou Gehrig's disease) and
spinal cord injury.
About Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company that
has historically worked to develop novel therapies
for neurodegenerative diseases. Synaptogenix has conducted
clinical and preclinical studies of its lead therapeutic candidate,
Bryostatin-1, in Alzheimer's disease. Preclinical studies have also
demonstrated bryostatin's regenerative mechanisms of action for the
rare disease Fragile X syndrome, and for other neurodegenerative
disorders such as multiple sclerosis, stroke, and traumatic brain
injury. The U.S. Food and Drug Administration has granted Orphan
Drug Designation to Synaptogenix for Bryostatin-1 as a treatment
for Fragile X syndrome. Bryostatin-1 has already undergone testing
in more than 1,500 people in cancer studies, thus creating a large
safety data base that will further inform clinical trial designs.
Additional information about Synaptogenix, Inc. may be found on its
website: www.synaptogen.com
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Such forward-looking statements are subject to risks
and uncertainties and other influences, many of which the Company
has no control over. There can be no assurance that the clinical
program for Bryostatin-1 will be successful in demonstrating safety
and/or efficacy, that the Company will not encounter problems or
delays in clinical development, or that Bryostatin-1 will ever
receive regulatory approval or be successfully commercialized.
Actual results and the timing of certain events and circumstances
may differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Additional
factors that may influence or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing,
the significant length of time associated with drug development and
related insufficient cash flows and resulting illiquidity, the
Company's patent portfolio, the Company's inability to expand its
business, significant government regulation of pharmaceuticals and
the healthcare industry, lack of product diversification,
availability of the Company's raw materials, existing or increased
competition, stock volatility and illiquidity, and the Company's
failure to implement its business plans or strategies. These and
other factors are identified and described in more detail in the
Company's filings with the Securities and Exchange Commission. The
Company does not undertake to update these forward-looking
statements.
Contact
800-811-5591
ir@synaptogen.com
View original
content:https://www.prnewswire.com/news-releases/synaptogenix-announces-new-collaboration-with-lsu-health-new-orleans-for-study-of-proprietary-analogs-in-spinal-cord-injury-302200323.html
SOURCE Synaptogenix, Inc.
